| 8.87 0.1 (1.14%) | 04-02 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 11.32 | 1-year : | 13.23 |
| Resists | First : | 9.69 | Second : | 11.32 |
| Pivot price | 8.32 |
|||
| Supports | First : | 8.24 | Second : | 7.34 |
| MAs | MA(5) : | 8.32 |
MA(20) : | 8.41 |
| MA(100) : | 8.17 |
MA(250) : | 5.61 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 71.4 |
D(3) : | 50 |
| RSI | RSI(14): 57.1 |
|||
| 52-week | High : | 13.67 | Low : | 1.77 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ KYTX ] has closed below upper band by 23.2%. Bollinger Bands are 15% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 9.19 - 9.23 | 9.23 - 9.27 |
| Low: | 8.42 - 8.45 | 8.45 - 8.49 |
| Close: | 8.81 - 8.87 | 8.87 - 8.94 |
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Thu, 02 Apr 2026
Kyverna Therapeutics (NASDAQ: KYTX) registers $100M ATM via Jefferies - Stock Titan
Wed, 01 Apr 2026
HC Wainwright Analysts Increase Earnings Estimates for KYTX - MarketBeat
Tue, 31 Mar 2026
[144] Kyverna Therapeutics, Inc. SEC Filing - Stock Titan
Tue, 31 Mar 2026
Brokers Issue Forecasts for KYTX FY2027 Earnings - MarketBeat
Sun, 29 Mar 2026
Kyverna Therapeutics files $300M mixed securities shelf - MSN
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 60 (M) |
| Shares Float | 24 (M) |
| Held by Insiders | 8.7 (%) |
| Held by Institutions | 73.9 (%) |
| Shares Short | 4,210 (K) |
| Shares Short P.Month | 3,920 (K) |
| EPS | -3.65 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.47 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -40.8 % |
| Return on Equity (ttm) | -70.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -2.27 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.82 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -157 (M) |
| Levered Free Cash Flow | -96 (M) |
| PE Ratio | -2.44 |
| PEG Ratio | 0 |
| Price to Book value | 2.55 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.42 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|